Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
R Garcia-Campelo, O Arrieta, B Massuti… - Lung Cancer, 2020 - Elsevier
Objectives Progression-free survival (PFS) and response rate to epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) varies in patients with non-small-cell lung …
receptor (EGFR) tyrosine kinase inhibitors (TKIs) varies in patients with non-small-cell lung …
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung …
RG Campelo, OG Arrieta Rodriguez, B Massuti… - 2018 - ascopubs.org
9012 Background: Low BRCA1 mRNA levels correlate with longer progression free survival
(PFS) in erlotinib treated EGFR mutant NSCLC patients (p), while risk of shortened PFS was …
(PFS) in erlotinib treated EGFR mutant NSCLC patients (p), while risk of shortened PFS was …
Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell …
9001 Background: Standard first-line therapy for EGFR mutant advanced non-small cell lung
cancer (NSCLC) is an EGFR-directed oral TKI. We evaluated whether adding pemetrexed …
cancer (NSCLC) is an EGFR-directed oral TKI. We evaluated whether adding pemetrexed …
Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive …
RG Campelo, E Felip, B Massuti, M Majem… - 2014 - ascopubs.org
8079 Background: Progression-free survival (PFS) and response rate (RR) to EGFR tyrosine
kinase inhibitors (TKIs) vary in P with NSCLC driven by EGFR mutations, suggesting that …
kinase inhibitors (TKIs) vary in P with NSCLC driven by EGFR mutations, suggesting that …
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
E Miyauchi, S Morita, A Nakamura, Y Hosomi… - Journal of clinical …, 2022 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …
report, typically based on the primary end point, may be published when key planned …
Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: a retrospective cohort study in Taiwan
YY Hsieh, WT Fang, YW Lo, YH Chen… - International journal of …, 2020 - Wiley Online Library
The study was to compare the effectiveness of different epidermal growth factor receptor—
tyrosine kinase inhibitors (EGFR‐TKIs) in patients with advanced non‐small‐cell lung …
tyrosine kinase inhibitors (EGFR‐TKIs) in patients with advanced non‐small‐cell lung …
Gefitinib plus bevacizumab vs. gefitinib alone for EGFR mutant non-squamous non-small cell lung cancer
C Kitagawa, M Mori, M Ichiki, N Sukoh, A Kada… - in vivo, 2019 - iv.iiarjournals.org
Background/Aim: A phase II trial was conducted to assess the efficacy and safety of gefitinib
plus bevacizumab for EGFR mutation-positive non-small cell lung cancer (NSCLC). Patients …
plus bevacizumab for EGFR mutation-positive non-small cell lung cancer (NSCLC). Patients …
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
LV Sequist, RG Martins, D Spigel… - Journal of clinical …, 2008 - ascopubs.org
Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
[HTML][HTML] Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with …
S Sugawara, S Oizumi, K Minato, T Harada, A Inoue… - Annals of oncology, 2015 - Elsevier
ABSTRACT EGFR-TKI therapy produces a dramatic clinical response in patients with
NSCLC harboring EGFR mutation. However, clinical outcomes should be improved further …
NSCLC harboring EGFR mutation. However, clinical outcomes should be improved further …
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …
相关搜索
- lung cancer gefitinib alone
- egfr mutations randomized phase
- gefitinib and chemotherapy randomized phase
- lung cancer mutated egfr
- nej005 tcog0902 randomized phase
- lung cancer updated analysis
- egfr mutations nej005 tcog0902
- t790m mutation clinical outcomes
- lung cancer combination of gefitinib
- gefitinib and chemotherapy egfr mutations
- egfr mutations clinical outcomes
- gefitinib and chemotherapy nej005 tcog0902